FDA OKs expansion of Abiomed's Impella RP trial

Abiomed says the FDA approved its bid to expand the Recover Right trial of its Impella RP heart pump.

Abiomed (NSDQ:ABMD) said the FDA will allow it to nearly double enrollment in a clinical trial of its Impella RP right-side heart pump, the Recover Right study, as it seeks a humanitarian device exemption from the watchdog agency.

Food & Drug Administration (FDA), Abiomed Inc.

News Well, Clinical Trials, Cardiac Assist Devices

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/SjAIgO